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ABSTRACT  
Large studies in von Willebrand disease patients, including Spanish and Portuguese registries, 
led to identification of >250 different mutations. It is a challenge to determine the pathogenic 
effect of potential splice site mutations on VWF mRNA. This study aimed to elucidate the true 
effects of 18 mutations on VWF mRNA processing, investigate the contribution of next-
generation sequencing to in vivo mRNA study in von Willebrand disease, and compare the 
findings with in silico prediction. RNA extracted from patient platelets and leukocytes was 
amplified by RT-PCR and sequenced using Sanger and next generation sequencing techniques. 
Eight mutations affected VWF splicing: c.1533+1G>A, c.5664+2T>C and c.546G>A (p.=) 
prompted exon skipping; c.3223-7_3236dup and c.7082-2A>G resulted in activation of cryptic 
sites; c.3379+1G>A and c.7473G>A (p.=) demonstrated both molecular pathogenic 
mechanisms simultaneously; and the p.Cys370Tyr missense mutation generated two aberrant 
transcripts. Of note, the complete effect of 3 mutations was provided by next generation 
sequencing alone because of low expression of the aberrant transcripts. In the remaining 10 
mutations, no effect was elucidated in the experiments. However, the differential findings 
obtained in platelets and leukocytes provided substantial evidence that 4 of these would have 
an effect on VWF levels. In this first report using next generation sequencing technology to 
unravel the effects of VWF mutations on splicing, the technique yielded valuable information. 
Our data bring to light the importance of studying the effect of synonymous and missense 
mutations on VWF splicing to improve the current knowledge of the molecular mechanisms 
behind von Willebrand disease. 
 
ClinicalTrials.gov identifier: NCT02869074   
 
  
INTRODUCTION 
Von Willebrand disease (VWD), the most common congenital bleeding disorder, is caused by a 
genetic defect in the von Willebrand factor gene (VWF).
1
 VWF mutational analysis can be 
valuable for diagnosing and investigating the molecular etiology of VWD, as was seen in the 
Spanish (PCM-EVW-ES project) and Portuguese cohort of VWD patients.
2-4
 One interesting 
challenge in this condition is to elucidate the pathogenic mechanism of VWF mutations. In 
silico analysis is considered a suitable supporting tool to predict the pathogenicity of the 
variants identified.
5, 6
 However, functional studies remain essential to unequivocally determine 
their deleterious effect.
7
  
Functional studies can be performed by analyzing the potential effect of splice site mutations 
(PSSM) in RNA. In addition to splice site consensus sequence mutations, deep intronic, 
missense, and synonymous mutations can also disturb splicing. Along this line, 25% of 
synonymous mutations positioned at exon-intron boundaries result in altered splicing, which, 
in itself, can cause disease, modify the severity of the disease phenotype, or be linked with 
disease susceptibility.
8
 In VWF, heterozygotes for PSSM may be associated with mild forms of 
VWD type 1 or be phenotypically silent, but when 2 such mutations are found in different 
alleles, the phenotype is associated with VWD type 3.
9
  
Almost all related studies of splicing effects have examined peripheral blood platelets, as VWF 
is exclusively expressed in these cells and endothelial cells.
10, 11
 Platelets are anucleated, but 
they contain small amounts of translationally active megakaryocytic mRNA.
12,13
 In contrast, the 
amount of mRNA obtained from leukocytes is higher and contains mRNA transcripts for genes 
that are not normally expressed in these cells, known as ‘‘ectopic transcripts’’.  Their analysis 
has been used to investigate mutations in several inherited disorders,
14,15
 as they facilitate the 
study of mRNA of those genes expressed in hard to reach tissues.
16
 PSSM can affect mRNA 
reorganization and introduce premature termination codons (PTCs) into open reading frames, 
a common cause of genetic disorders. Most nonsense transcripts are recognized and degraded 
by nonsense-mediated mRNA decay (NMD),
17
 a degradation pathway to control synthesis of 
truncated proteins.
18
 The efficiency of NMD varies between cell types; hence, the use of RNA 
from platelets and leukocytes for in vivo study of VWF PSSM offers complementary results, 
particularly when NMD occurs in the allele carrying the mutation in platelets, as we reported.
7
  
Since its development, next-generation sequencing (NGS) has been increasingly used in 
molecular genetics to identify mutations causing disease. However, few groups have explored 
its potential for analyzing splicing variants following RT-PCR.
19, 20
 In this new scenario, the 
procedure we previously described to analyze the effects of PSSM in VWF
7
 has been optimized 
and adapted to an NGS-based technique to investigate its value in this field. Our main 
objective was to elucidate the true effects of 18 selected mutations (intronic, synonymous, 
delins, and missense) on mRNA processing and their genotype/phenotype correspondence by 
analysis of leukocytes and platelets from clinical samples. Finally, the in vivo effects of the 
mutations were compared with the in silico predictions.   
  
METHODS  
Patients 
We studied 15 patients diagnosed with different types of VWD, 5 from Complexo Hospitalario 
Universitario A Coruña, 8 from Hospital Universitari Vall d’Hebron (HUVH), and 2 from Centro 
Hospitalar e Universitário de Coimbra. Samples from 4 healthy individuals were used as 
controls. The study was performed according to the guidelines of the Declaration of Helsinki 
and was approved by the local Research Ethics Committee. All participants provided written 
informed consent.  
Splice site prediction software 
The predicted impact of potential splice site mutations was analyzed with NetGene2
21
  and the 
splicing prediction module of Alamut Visual v.2.6.1 software (Interactive Biosoftware, Rouen, 
France), which integrates data from 3 methods: Splice Site Prediction by Neural Network 
(NNSplice), MaxEntScan, and Human Splicing Finder (HSF).  
Platelet and leukocyte separation and RNA isolation 
Leukocyte and platelet RNA from patients and controls was isolated from 10 mL of peripheral 
blood collected in EDTA tubes, as previously described.
7
  
VWF mRNA amplification  
After RNA isolation, cDNA was synthesized using the High-Capacity cDNA Reverse Transcription 
Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s 
recommendations. The region including the mutation was amplified by Platinum Taq DNA 
Polymerase (Thermo Fisher Scientific) in leukocyte and platelet cDNA (Online Supplementary 
Methods and Table S1).  PCR products were separated on 1% agarose gel and visualized by 
SYBR Safe DNA Gel Stain (Thermo Fisher Scientific).  
Sanger sequencing and analysis 
PCR products were sequenced as previously described.
22
 However, multiple-band PCR 
products were previously agarose-purified using the MiniElute Gel Extraction kit (Qiagen). The 
sequences obtained were assembled and aligned against the consensus wild-type (WT) VWF 
mRNA sequence (GenBank NM_000552) using SeqScape v2.7 software (Thermo Fisher 
Scientific). 
Next-generation sequencing and analysis  
PCR amplicons obtained per patient were equimolarly mixed in a single tube in a total amount 
of 250 ng. Subsequently, the libraries were fragmented and the adapter and barcodes were 
ligated using the NGSgo protocol (GenDX, Utrecht, Netherlands) following the manufacturer’s 
recommendations. Resulting libraries were combined and sequenced on a MiSeq platform 
(Illumina, San Diego, CA). 
After sequencing, barcoded sequences were demultiplexed and analyzed individually. The 
paired sequence files (fastq format) were used as input for analysis with the CLC Genomic 
Workbench v.11 software (Qiagen, Aarhus, Denmark) (Online Supplementary Methods and 
Figure S1-S2).  
RESULTS 
An in-depth study was performed in PCM-EVW-ES,
3
 the Portuguese cohort,
4
 and HUVH 
patients to select previously undescribed VWF mutations and mutations with an unknown or 
controversial pathogenic mechanism. Eighteen mutations (15 patients) were selected: 8 
intronic (4 in canonical, GT and AG, splice site sequences), 5 synonymous, 2 missense, and 3 
delins. The patients’ phenotypic and molecular data are summarized in Table 1 and Online 
Supplementary Table S2. Total mRNA was obtained from platelets and leukocytes of all 
patients, with the exception of patients UMP08 and UMP14, in whom platelet RNA isolation 
failed due to blood lysis. All mutations were analyzed by both Sanger sequencing and NGS, and 
results were compared to the predictions generated by in silico analysis (Online Supplementary 
Table S3). 
Mutations in canonical splice site sequences  
The c.1533+1G>A mutation (intron 13) was identified in a type 3 VWD carrier (UMP01). The 
exon 11-15 region was analyzed with a specific primer pair to avoid amplification of a 
prevalent alternative-splicing product (skipping of exons 14 and 15) in VWF from leukocytes.
7
 
Whereas only the expected PCR product was observed in platelets, leukocyte amplification 
resulted in 4 PCR bands. Sanger analysis of leukocytes showed 2 mRNA aberrant transcripts: 1) 
lacking exon 13; and 2) lacking exon 13 and 14 (Online Supplementary Figure S3). By means of 
NGS it was determined that 19% were transcripts without exon 13, 45% transcripts without 
exons 13 and 14, and an additional aberrant transcript without exon 14 was detected in 8% 
transcripts (Online Supplementary Table S4). By both techniques, no effect was visible in 
platelets due to NMD.  
The c.3379+1G>A mutation (intron 25) was identified in a type 1H VWD patient (UMP02). We 
designed 2 new primers to analyze the exon 22-26 region. Amplification of leukocyte cDNA 
yielded 2 bands, one with the expected size and a smaller band, whereas in platelets only the 
expected PCR product was observed (Online Supplementary Figure S4). Sanger analysis of 
leukocytes showed that c.3379+1G>A caused exon 25 skipping, leading to a frameshift at 
position 1075 and adding 88 aberrant amino acids before a PTC was encountered 
(p.Pro1075ValfsTer88). On NGS, however, 2 aberrant transcripts were detected: the major 
one, which lacked exon 25, was detected in 43% of all reads, and the minor one, which 
resulted from activation of a cryptic donor splice site (DSS) 31 nucleotides upstream from the 
WT-DSS, was found in 1.4% of reads (p.Pro1117ValfsTer88) (Table 2 and Online Supplementary 
Table S4). In platelets, however, the mutated allele had undergone NMD, which precluded 
observation of aberrant transcripts.  
The c.5664+2T>C mutation was identified in a type 1 VWD patient (UMP03), in trans with the 
p.Leu2407Pro mutation. To analyze the PSSM in intron 33, the exon 30-35 region was 
amplified. The PCR product had the expected size in platelets, whereas an additional smaller 
one was observed in leukocytes (Figure 1). Sanger sequencing of the leukocyte PCR product 
confirmed exon 33 skipping (p.Gly1874AlafsTer32) (Table 2). NGS detected 2 aberrant 
transcripts: the major one (37% of reads) showed exon 33 skipping, and the minor (2% of 
reads) showed exons 33 and 34 skipping. Moreover, analysis of the p.Leu2407Pro mutation 
confirmed that NMD of the allele carrying the c.5664+2T>C mutation had occurred in platelets.  
Candidate intronic mutations 
The c.7081+6G>T mutation, identified in a type 1 VWD patient (UMP04), generated a new GT 
dinucleotide in intron 41 (Online Supplementary Table S3). The exon 38-43 region showed the 
expected PCR product in both cell types (772 bp). To confirm these results, two informative 
SNPs (rs216321 in exon 20 and rs216902 in exon 35) were genotyped. Both were in 
heterozygous state, indicating that the allele carrying the mutation was unaffected by NMD.  
The c.7730-56C>T mutation (intron 45) was identified in a type 1 VWD patient (UMP05). The 
exon 43-49 region, examined by Sanger and NGS, showed no visible effect on mRNA splicing. 
To confirm the presence of the allele carrying the intronic mutation, two informative SNPs 
were analyzed: rs216321 and rs1800380. Surprisingly, the sequence obtained in both cell types 
indicated that only one allele was expressed. To further explore these results, we tested 
whether intron 45 was retained within the mature mRNA (Online Supplementary Methods) 
and performed complete sequencing of VWF cDNA from leukocytes. Nonetheless, no changes 
were observed (data not shown).  
The c.7730-4C>G mutation (intron 45) was identified in a type 2A/2M patient (UMP06), 
combined with the p.Arg1374Cys mutation. The HSF predicted activation of a cryptic intronic 
acceptor splice site (ASS), but in the exon 43-49 region, splicing was not affected by the 
mutation. To confirm the presence of the allele carrying c.7730-4C>G, the p.Arg1374Cys 
mutation was analyzed, and both nucleotides were seen in platelets and leukocytes, 
suggesting expression of both alleles. We then performed the same experiment as was done in 
patient UMP05 to test intron 45 retention, but no changes in VWF cDNA were observed (data 
not shown).  
The c.8254-5T>G mutation (intron 51) was found in a type 1 VWD patient (UMP07). The exon 
49-52 region was amplified, and the expected 546-bp size was observed in both cell types. 
Sequence analysis by the 2 techniques revealed no changes in VWF cDNA. Interestingly, this 
patient’s 2 children, heterozygous for the c.8254-5T>G mutation, had bleeding symptoms. 
Hence, we performed complete sequencing of VWF cDNA from leukocytes. However, no 
changes were identified. 
Synonymous mutations  
The mutations c.546G>A (exon 6) and c.4866C>T (exon 28) were identified in trans in a type 1 
VWD patient (UMP08). These mutations were studied only in leukocyte RNA. To investigate 
c.546G>A, the exon 4-7 region was amplified, which resulted in the expected band and a 
slightly diffuse, smaller band. Sanger sequencing detected the c.546G>A change (Figure 2). 
However, NGS not only detected the nucleotide change, but also recognized a loss of 125 
nucleotides corresponding to exon 6 (p.Thr179ProfsTer31) in small 2.3% of reads (Online 
Supplementary Table S4). The predicted impact of the c.546G>A mutation was discrepant and 
only two in silico algorithms predicted an effect on mRNA splicing (Online Supplementary Table 
S3) that was confirmed in vivo even though with a slight effect. To study c.4866C>T, the exon 
25-31 region was amplified and sequenced, but no effect on mRNA processing was seen, as 
was predicted by in silico tools. Both nucleotides were identified in heterozygous state, 
indicating the presence of both alleles. Only offspring carrying the c.546G>A mutation (1 of 3 
children) had lower levels of VWF:Ag and VWF:RCo compared to the others. This may be 
explained by the mutation and/or other factors not explored in the current study. 
The c.3291C>T mutation (exon 25), was identified in patient UMP09 (female), as well as a 
novel mutation in F8 (c.1346C>G, p.Ala430Gly). Of note, her brother, who was not included in 
this study, also had these mutations. As both siblings experienced bleeding, and the HSF 
prediction regarding c.3291C>T interpreted creation of an exonic splicing silencer site that 
could potentially alter splicing, we hypothesized that this synonymous mutation could have an 
effect on VWF mRNA processing. Hence, the exon 22-26 region was amplified, but no change 
in the VWF cDNA sequence was observed. In addition, we tested whether intron 25 was 
retained within mature VWF mRNA (Online Supplementary Methods), but no differences 
compared to control leukocyte cDNA were found (data not shown). Finally, as both siblings 
presented similar FVIII:C levels, we investigated X chromosome inactivation in patient UMP09. 
The results demonstrated skewed inactivation of the WT X chromosome in this patient (Online 
Supplementary Figure S5). 
Missense mutations 
The mutation c.1109G>A (p.Cys370Tyr, exon 9) was identified in a type 3 VWD carrier 
(UMP10). The exon 6-12 region was investigated. Whereas the expected size was observed in 
platelets, amplification from leukocytes resulted in 2 additional bands of    650 and    500 bp 
(Figure 3). Sanger sequencing of leukocyte mRNA confirmed that the 650-bp band 
corresponded to a transcript lacking exon 9. NGS of leukocyte mRNA revealed 3 different 
transcripts: the WT, a transcript skipping exon 9 (p.Glu333AlafsTer87) (13% of reads), and a 
transcript skipping exons 8 and 9 (p.Ser292ThrfsTer87) (7% of reads)(Table 2). Sequencing of 
PCR products from platelets showed no changes, suggesting that the mutated allele had 
experienced NMD.  
Duplication mutation 
The c.3223-7_3236dup mutation, which generated an in-frame tandem duplication of 21 
nucleotides, including 7 nucleotides from intron 24 and the first 14 from exon 25, was 
detected in a type 1 VWD patient (UMP11). Study of this mutation by the 2 techniques 
demonstrated a change in the native ASS of intron 24 in both cell types, which resulted in 
maintaining the 21-bp insert corresponding to 7 aberrant amino acids in mature VWF mRNA 
(p.Pro1079_Tyr1080insLeuGlnValAspProGluPro) (Table 2 and Online Supplementary Figure S6). 
Furthermore, NGS showed that the aberrant mRNA transcript was present in    14% of reads 
in both cell types (Online Supplementary Table S4).  
Combined potential splice site mutations in individual patients 
The c.7082-2A>G mutation (intron 41) was identified in a type 3 VWD patient (UMP12) 
combined in trans with the p.Leu150Pro (c.449C>T, exon 5) mutation. To study c.7082-2A>G, 
the exon 38-43 region was amplified in platelets and leukocytes, which yielded a band of the 
expected size. However, Sanger and NGS sequencing of the PCR products revealed activation 
of a cryptic ASS within exon 42. This led to deletion of the 7 initial nucleotides of exon 42 
(r.7082_7088del), as was predicted by the 4 algorithms, and resulted in a frameshift and a PTC 
(p.Ala2361GlyfsTer40) (Figure 4). Additionally, NGS showed that the aberrant transcript was 
present in 24% of reads. On sequencing of platelet amplicons, there were no changes, a finding 
highly suggestive of NMD. As type 3 VWD is characterized by absent or non-functional 
expression of both VWF alleles, we postulated that the p.Leu150Pro missense mutation could 
have an effect on VWF mRNA. Nonetheless, no sequence change was identified. These results 
were confirmed by analysis of 2 informative SNPs, rs1800375 and rs1800376, which were 
found in heterozygous state in leukocyte transcripts and homozygous state in platelets. 
The c.[3426T>C; 3485_3486delinsTG] mutations (exon 26) were found in a type 2A VWD 
patient (UMP13), combined in trans with p.Cys2773Ser. In silico analysis predicted no impact 
on the splice site for c. 3485_3486delinsTG, but 2 of the 4 algorithms predicted that c.3426T>C 
would have an effect on splicing. The exon 25-28 region was investigated, but no effect was 
found on mRNA processing. Study of the p.Cys2773Ser mutation and 2 informative SNPs 
(rs2228317 and rs4021576) confirmed that the 2 alleles were present, suggesting that exon 26 
mutations do not have an effect on VWF splicing. 
The mutations c.7473G>A (p.=, exon 43), and c.6699_6702dup (p.Cys2235Argfs8Ter, exon 38) 
were identified in trans in a severe type 1 VWD patient (UMP14) and studied only in leukocyte 
RNA. For c.7473G>A, we amplified exons 41-45, and 2 bands emerged: one with the expected 
size, and a smaller band of     350 bp (Figure 5). Sequencing analysis by both techniques 
revealed 2 aberrant transcripts: one lacked exon 43 (p.Val2430GlyfsTer335) and the other 
showed activation of a cryptic DSS within exon 43, leading to deletion of its 4 final nucleotides 
(p.Ser2479AlafsTer23) (Table 2). Study of c.6699_6702dup in leukocyte mRNA showed no 
splicing changes, but the duplication introduced 4 nucleotides that changed the reading frame 
and generated a PTC (p.Cys2235ArgfsTer8). 
The c.546G>A (p.=, exon 6) and c.7082-2A>G (intron 41) mutations in trans with c.8155+3G>C 
(intron 50) were detected in a type 3 VWD patient (UMP15). This patient had been described 
in our previous article, but at that time we were only able to identify the effect of c.8155+3G>C 
(p.Gly2706ValfsTer24) on splicing. On reanalysis of this case with NGS, we were able to 
characterize the effect of c.546G>A (p.Thr179ProfsTer31) and c.7082-2A>G 
(p.Ala2361GlyfsTer40) in cis in leukocyte mRNA. The results are consistent with those observed 
in patients UMP08 and UMP12, who harbored each mutation individually. In addition, in 
leukocytes, transcripts resulting from c.546G>A were detected in 2% of reads, transcripts from 
c.7082-2A>G in 6% and transcripts from c.8155+3G>C in 95% of reads.  In platelet analyses, 
NGS detected transcripts without exon 6 resulting from the c.546G>A mutation in 11% of the 
total reads but no aberrant transcript derived from the mutation c.7082-2A>G indicating that 
NMD rate could differ between 5' and 3' regions of mRNA. These results indicate the 
c.[546G>A; 7082-2A>G] allele is under-represented compared to the allele carrying the 
c.8155+3G>C mutation, showing that this allele underwent NMD in both cell types, as was 
previously hypothesized.
7
 
 
DISCUSSION 
This study reports the results of in-depth analysis of 18 PSSM in samples from VWD patients. 
The novel and robust procedure used, combining two-step RT-PCR and NGS sequencing, was 
faster and more sensitive than the method used in our previous article.
7
 This new approach 
provides several advantages, such as allele-specific individual sequences, higher sensitivity to 
detect transcript variants present at low copy numbers, and simplified sample preparation. 
Moreover, the NGS data on total reads obtained for each transcript is additional information 
that can provide an approximation of the expression levels of each VWF mRNA. Studies are 
currently ongoing to confirm that the relative expression of each transcript obtained by NGS is 
comparable to that provided by real-time RT-PCR.  
The proven usefulness of leukocyte analysis to interpret mutations masked by NMD in 
platelets was seen in relation to the c.3379+1G>A mutation, which had been previously 
investigated by RT-PCR in platelets.
23
 In that study, the true pathogenic effect of this mutation 
could not be determined due to NMD. In the present study, using leukocyte mRNA and NGS 
technology, we found that the mutation induces two aberrant transcripts.  
Similarly, the pathogenic mechanism of 7 PSSM (c.1533+1G>A, c.5664+2T>C, c.7082-2A>G, 
c.546G>A, c.7437G>A, and p.Cys370Tyr) was determined in leukocytes, and only the c.3223-
7_3236dup mutation effect was observed in both cell types. Because this mutation is located 
in the D3 domain implicated in multimerization, it is possible that the pathogenic mechanism 
leading to type 1 VWD may be related to impaired VWF secretion due to intracellular 
retention, as has been described for other D3 mutations such as p.Cys1130Phe.
24
 To confirm 
this hypothesis, expression studies by means of heterologous cell lines or blood outgrowth 
endothelial cells (BOECs) will remain the gold standard.  
As would be expected, mutations located in the consensus splicing sequence affected mRNA 
processing. These included c.1533+1G>A, c.5664+2T>C, leading to exon skipping, and c.7082-
2A>G, activating a cryptic splice site. Both these molecular effects have been reported 
previously in splicing mutations causing VWD.
7, 25, 26
  The c.7082-2A>G in trans with 
p.Leu150Pro leads to the development of type 3 VWD. The p.Leu150Pro mutation does not 
affect splicing. However, other mutations located in the propeptide, such as p.Asp141Tyr, have 
been identified in type 3 patients,
27
 and, as has been described in these cases, we suspect that 
p.Leu150Pro may compromise propeptide folding and affect intracellular survival and the 
capacity to mediate multimerization. The c.1533+1G>A mutation in leukocytes generated 3 
aberrant transcripts. One of them, which leads to the inframe deletion of exons 13-14, should 
have been detected in platelets since it would not generate a PTC and would not be degraded. 
However, because the mutation is located in a region with weak splicing signal sequences, as 
previously demonstrated,
7, 25, 26
 we suggest that the results obtained in leukocytes could be an 
artifact that would not occur in the natural cellular type of VWF expression. Based on these 
observations, we propose that the real effect of c.1533+1G>A is the skipping of exon 13, which 
predicts a frameshift at position 478 and addition of 138 aberrant amino acids before a PTC is 
encountered (p.Gly478AlafsTer138). 
Two synonymous mutations included in our study, c.546G>A and c.7437G>A, affect splicing of 
VWF mRNA. To our knowledge, only 3 synonymous mutations affecting VWF mRNA processing 
have been reported:  c.7056C>T,
28
 c.7464C>T,
29
 and c.3390C>T.
26
 Of note, the results of the 
present study have almost doubled the number of reported mutations of this type causing 
VWD. The pathogenic effect of c.546G>A could only be documented by NGS; it eluded Sanger 
detection because of the low expression in leukocytes and platelets. The c.7437G>A mutation 
located at the last nucleotide of exon 43 was found in a patient with severe type 1 VWD 
(UMP14) in trans with c.6699_6702dup (p.Cys2235ArgTer8). This synonymous mutation 
produced 2 splicing variants. First, creation of a new DSS 4 nucleotides upstream of the WT-
DSS in exon 43 that generated a PTC in exon 44 and would lead to NMD in platelets; and 
second, exon 43 skipping and generation of a PTC in exon 52. In this latter case, we would 
expect that NMD had been abolished in platelets, since this cellular mechanism is not effective 
when a PTC is encountered within 50 bp of the last exon-exon junction.
30
  
Study of the p.Cys370Tyr (c.1109G>A in exon 9) mutation, resulted in generation of 2 VWF 
transcripts, one of them identified only by NGS because of their low expression. Of note, only 
one other missense mutation, p.Gly1108Arg, has been reported to affect VWF splicing. Thus, 
these 2 mutations support the concept that missense mutations on the last exonic nucleotides 
can also have repercussions on the splicing process.
31
 Interestingly, the pathogenic effect of 
this mutation is the same as that described for c.1109+2T>C (intron 9).
32
 In addition to the 
patient reported here, the p.Cys370Tyr mutation was identified in 6 additional related patients 
included in the PCM-EVW-ES: in homozygous state in a type 3 VWD patient and in 
heterozygosis in 4 type 3 carriers and 1 patient with type 1 VWD, based on their phenotype 
levels. Certain genetic modifiers of VWF levels
33
 and inter-individual variability in NMD 
efficiency between patients carrying identical mutations may lead to differences in the disease 
severity and clinical phenotype.
34
  
Lastly, study of c.7081+6G>T, c.7730-4C>G, c.7730-56C>T, c.8254-5T>G, c.3291C>T, c.4866C>T 
and c.[3426T>C; 3485_3486delinsTG] showed no visible effect on mRNA processing, although 
this does not necessarily mean that they have no effect on splicing. For instance, mRNA SNP 
analysis in patient UMP05 with c.7730-56C>T showed an absence of 1 allele in leukocytes and 
platelets, suggesting that the allele may have experienced NMD in both cell types or lack 
expression due to a mutation that was not detected by our sequencing protocol. Of particular 
note, deep intronic mutations such as c.6599-20A>T have been found to cause VWD.
35
 In 
patient UMP07 carrying the c.8254-5T>G mutation, no informative SNP was identified and we 
were unable to determine whether there was a lack of expression of 1 allele, which could 
explain cosegregation of the mutation in the family with bleeding symptoms.   
Study of c.[3426T>C; 3485_3486delinsTG] and c.7730-4C>G showed no visible effect on 
splicing. However, these mutations have been identified in homozygous state in a type 3 
patient (c.[3426T>C; 3485_3486delinsTG])
3
 and in a severe type 1 VWD patient (c.7730-4C>G)
4
 
with  VWF:Ag at 7% and VWF:RCo at 5%, combined with the heterozygous p.Ala631Val 
(previously reported in a healthy control).
36
 Based on these findings, there is substantial 
evidence that these mutations would have an effect on VWF levels. Therefore, to 
unequivocally determine the potential deleterious effect of these variants, functional studies 
remain essential. These studies are traditionally undergoing by in vitro analyses performed 
using heterologous cell lines (COS7, AtT-20 and HEK293). However, the advent of the 
possibility of obtaining BOECs from patients represents a valuable alternative, since this is the 
functional expression site of VWF.
37
 Moreover, BOECs allows protein expression and mRNA 
studies simultaneously. 
In silico algorithms used to assess the impact of mutations on splicing are more sensitive and 
accurate in determining the putative effect of intronic mutations than that of synonymous or 
missense mutations, such as c.546G>A and p.Cys370Tyr. Therefore, the results here should not 
be considered definitive, and as with all analytical approaches, should form one aspect of a 
wider investigation.
5
  
In conclusion, we present an extensive study reporting the effect of 18 candidate mutations on 
VWF mRNA processing. In vivo mRNA studies incorporating NGS technology together with 
traditional sequencing enabled us to determine the pathogenic effect of 8 PSSM (44%). Our 
study emphasizes the importance of examining selected mutations, including synonymous and 
missense mutations, to determine their pathogenic role in splicing. Taken together, our results 
add to the current knowledge about the molecular events leading to VWD.   
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TABLES 
 
Table 1. Laboratory and molecular data of VWD patients 
 
Patients 
code 
VWD VWF:Ag VWF:RCo FVIII:C NT change AA change Exon Intron Domain 
UMP01 3 carrier 70 70.5 111 c.1533+1G>A  - - 13 intronic 
UMP02 1H 36 49 101 
c.3379+1G>A * - - 25 intronic 
c.-2627C>T * - - - upstream 
UMP03 1 26 21.2 64.8 
c.5664+2T>C *  - - 33 intronic 
c.7220T>C * p.Leu2407Pro 42 - C2 
UMP04 1 50 52 47 c.7081+6G>T  - - 41 intronic 
UMP05 1 27 32 72 c.7730-56C>T - - 45 intronic 
UMP06 2A/2M 12 4 24 
c.4120C>T * p.Arg1374Cys 28  A1 
c.7730-4C>G * - - 45 intronic 
UMP07 1 37 28 60 c.8254-5T>G - - 51 intronic 
UMP08 1 42.4 41.7 73.4 
c.546G>A † p.Ser182 6 - D1 
c.4866C>T † p.Asp1622 28 - A1-A3 
UMP09 ‡ 1 51 49.8 71 c.3291C>T p.Cys1097 25 - D3 
UMP10 3 carrier 46.4 45 105 c.1109G>A p.Cys370Tyr 9 - D1 
UMP11 1 31 24 57 c.3223-7_3236dup 
p.Pro1079_Tyr1080ins
LeuGlnValAspProGlu
Pro 
25 - D3 
UMP12 3 3.7 5 6.7 
c.449T>C † p.Leu150Pro 5 - D1 
c.7082-2A>G † - - 41 intronic 
UMP13 2A 117 6.5 90 
c.3426T>C § p.Cys1142 26 - D3 
c.3485_3486delinsTG § p.Pro1162Leu 26 - D3 
c.8318G>C † p.Cys2773Ser 52 - CK 
UMP14 1 6 6 4,5 
c.6699_6702dup † p.Cys2235ArgTer8 38 - D4 
c.7437G>A † p.Ser2479 43 - C3 
UMP15|| 3 2 <1 5 
c.546G>A § p.Ser182 6 - D1 
c.7082-2A>G § - - 41 intronic 
c.8155+3G>C † - - 50 intronic 
 
All mutations were identified in heterozygous state. In bold, mutations selected to study their effect on VWF mRNA. The subtype 1H (historical) refers to patients previously diagnosed as type 1 VWD that, at the 
time of enrollment at the PCM-EVW-ES project, show a slight decrease or even a normal VWF plasma levels. AA indicates amino acid; NT, nucleotide and; VWD, von Willebrand disease. *The allelic phase 
(cis/trans) of mutations could not be determined since no informative relatives are available. †Mutations in trans. ‡Patient with an additional mutation in the F8 gene. §Mutations in cis. ||Patient previously 
studied at mRNA level by Corrales et al.
7
  
 
Table 2. Effect of VWF mutations on mRNA from leukocytes and platelets 
 
Mutation type NT change AA change Exon Intron Leukocyte effect Platelet effect Protein prediction 
Intronic 
c.1533+1G>A - - 13 Exon 13 skipping (r.1433_1533del) NMD p.Gly478AlafsTer138 
c.3379+1G>A* - - 25 
Exon 25 skipping (r.3223_3379del) NMD p.Pro1075ValfsTer88 
Activation of a cryptic site at +126 nt in exon 25 
(r.3349_3379del) ‡ NMD p.Pro1117ValfsTer88 
c.5664+2T>C - - 33 
Exon 33 skipping (r.5621_5664del) NMD p.Gly1874AlafsTer32 
Exon 33+34 skipping (r.5621_5842del) ‡ NMD 
p.Phe1875_Cys1948del 
c.7081+6G>T - - 41 No visible effect No visible effect - 
c.7082-2A>G † - - 41 Activation of a cryptic site +7 nt in exon 42 (r.7082_7088del) NMD p.Ala2361GlyfsTer40 
c.7730-4C>G - - 45 No visible effect No visible effect - 
c.7730-56C>T - - 45 No visible effect No visible effect - 
c.8254-5T>G - - 51 No visible effect No visible effect - 
Synonymous 
c.546G>A † p.Ser182 6 - Exon 6 skipping (r.533_657del) ‡ NA p.Thr179ProfsTer31 
c.3291C>T p.Cys1097 25 - No visible effect No visible effect - 
c.3426T>C p.Cys1142 26 - No visible effect No visible effect - 
c.4866C>T p.Asp1622 28 - No visible effect NA - 
c.7437G>A p.Ser2479 43 - 
Exon 43 skipping (r.7288_7437) NA p.Val2430GlyfsTer335 
Activation of a cryptic site at +146 nt in exon 43 
(r.7434_7437del) NA p.Ser2479AlafsTer23 
Missense 
c.449T>C  p.Leu150Pro 5 - No visible effect No visible effect - 
c.1109G>A p.Cys370Tyr 9 - 
Exon 9 skipping (r.998_1109del) NMD p.Glu333AlafsTer87 
Exon 8+9 skipping (r.875_1109del) NMD p.Ser292ThrfsTer87 
DelIns 
c.3485_3486delinsTG p.Pro1162Leu 26 - No visible effect No visible effect - 
c.3223-7_3236dup 
p.Pro1079_Tyr1080insLe
u 
GlnValAspProGluPro 
25 - (r.3477_3478instttgcaggtggaccccgagcc) (r.3477_3478instttgcaggtggaccccgagcc) 
p.Pro1079_Tyr1080insLeu 
GlnValAspProGluPro 
c.6699_6702dup  p.Cys2235ArgTer8 38 - No visible effect NMD p.Cys2235ArgTer8 
 
AA indicates amino acid; NA, not available; NMD, nonsense-mediated decay and; NT, nucleotide. *Previous functional studies by Nesbitt et al.
23
 †Previous functional studies by Corrales et al.
7
 ‡Leukocyte effect 
observed in a really low % of reads by NGS.
FIGURE LEGENDS 
Figure 1. Analysis of the c.5664+2T>C mutation in patient UMP03. A) RT-PCR products 
amplified with primers located in exons 30 and 35 in leukocyte (L) and platelet (P) RNA, 
separated on 1% agarose gel. B) Traditional Sanger sequencing of PCR products from patient 
leukocytes (L) and platelets (P), and control leukocytes (L). Analysis of the band 2 from patient 
leukocyte on agarose gel demonstrates exon 33 skipping. In platelets, only the allele without 
c.5664+2T>C mutation could be amplified. C) NGS of PCR products from leukocytes showed 
exon 33 skipping, indicated by arrows depict aberrant transcripts. However, exon 33-34 
skipping was also detected, but in a really low of transcripts. D) Schematic representation of 
the mutation in genomic DNA and its effect on the VWF mRNA sequence. M indicates a 100-bp 
DNA ladder. 
Figure 2. Analysis of the c.546G>A (p.=) mutation, located at nucleotide 14 from the beginning 
of exon 6, in patient UMP08. A) RT-PCR products amplified with primers located in exons 4 and 
7 in leukocyte RNA (L), separated on 1% agarose gel. B) Traditional Sanger sequencing of PCR 
product from patient L (1) showed the single nucleotide change. C) NGS of PCR products from 
leukocytes identified the single nucleotide variant, as well as exon 6 skipping. Arrows show 
aberrant transcripts. D) Schematic representation of the mutation in genomic DNA and its 
effect on the VWF mRNA sequence. M indicates a 100-bp DNA ladder. 
Figure 3. Analysis of the c.1109G>A (p.Cys370Tyr) mutation in patient UMP10, located in the 
last nucleotide of exon 9. A) RT-PCR products amplified with primers located in exons 6 and 12 
in leukocyte (L) and platelet (P) RNA, separated on 1% agarose gel. B) Traditional Sanger 
sequencing of PCR product from patient L (2) showed exon 9 skipping. The L (3) band could not 
be purified in the agarose gel due to low concentration, thus it was not analyzed by Sanger. In 
platelets, only the non-mutated allele could be amplified.  C) NGS of PCR products from 
leukocytes identified transcripts lacking exon 9, as well as transcripts lacking exons 8 and 9. D) 
Schematic representation of the mutation in genomic DNA and its effect on the VWF mRNA 
sequence. M indicates a 100-bp DNA ladder. 
Figure 4. Analysis of the c.7082-2A>G mutation in patient UMP12. Agarose gel electrophoresis 
results of RT-PCR amplification of exon 38 to 43 using RNA from leukocytes and platelets were 
the same as those of healthy controls (data not shown). A) Traditional Sanger sequencing of 
PCR product from patient leukocyte (L) demonstrate activation of a cryptic splice site 7 
nucleotides downstream of the native splice site within exon 42. In patient platelet (P), only 
the allele carrying the p.Leu150Pro mutation could be amplified. B) NGS of PCR products from 
leukocytes showed deletion of the 7 initial nucleotides of exon 42. Arrows show aberrant 
transcripts. C) Schematic representation of the mutation in genomic DNA and its effect on the 
VWF mRNA sequence. WO indicates without. 
Figure 5. Analysis of the c.7437G>A (p.=) mutation in patient UMP14, located in the last 
nucleotide of exon 43. A) RT-PCR products amplified with primers located in exons 41 and 45 
in leukocyte RNA (L), separated on 1% agarose gel. B) Traditional Sanger sequencing of PCR 
product from patient leukocyte (L) shows two aberrant transcripts: activation of a cryptic splice 
site—4 nucleotides upstream to WT-DSS—in exon 43 (1), and exon 43 skipping (2). C) NGS of 
PCR products gave the same results than Sanger sequencing. D) Schematic representation of 
the mutation in genomic DNA and its effect on the VWF mRNA sequence. M indicates a 100-bp 
DNA ladder and; WO, without. 





 SUPPLEMENTARY DATA 
 
SUPPLEMENTARY METHODS 
VWF mRNA amplification  
The primers used have been reported previously,1 except for those specifically designed to 
analyze certain mutations (Online Supplementary Table S1). The PCR mix contained 1X PCR 
Buffer, 1.5 mM MgCl2, 200 μM dNTPs, 2 U Platinum Taq DNA polymerase, 0.75 μM of each 
primer, and cDNA in a total volume of 25 μL. After initial denaturation at 94ºC for 3 min, 38 
cycles of 94ºC for 20 sec, 62ºC for 30 sec, and 72ºC for 1 min were performed, followed by a 
final extension at 72ºC for 3 min. 
CLC Bio Data analysis parameters 
Primer sequences and low-quality regions were trimmed and aligned against the WT VWF mRNA 
sequence with specific parameter settings. The Basic Variant Detection algorithm was applied 
for single nucleotide variant-calling and the Indels and Structural Variants tool was performed 
to identify insertions and deletions produced by alternative splicing due to mutations. Analytical 
settings of both algorithms are described in Online Supplementary Figure S1. 
Finally, a specific probe was designed to each pre-characterized aberrant transcript and used to 
perform a second alignment from the original dataset. The results indicate the number of reads 
that aligned to each mRNA probe. 
Intron retention of exon 25 
To determine whether intron 25 was retained within the mature mRNA of patient UMP09, RT-
PCR reactions using 2 allele-specific primer combinations were performed. In the first primer 
pair, the forward was designed at the junction of exon 24-25 (VWFR24/25-1) and the reverse 
primer was designed inside intron 25 (VWF_E25-2). In the second primer pair, the forward 
primer targeted intron 25 (VWF_E26-1) and the reverse was located across the junction of exon 
26-27 (VWFR26/27-2).  
Intron retention of exon 45 
To determine whether intron 45 was retained within the mature mRNA of patients UMP05 and 
UMP06, RT-PCR reactions using 2 allele-specific primers combinations were performed. In the 
first primer pair, the forward was designed at the junction of exon 44-45 (VWFR44/45-1C) and 
the reverse primer was designed inside intron 45 (VWF_E45-2). In the second primer pair, the 
forward primer targeted intron 45 (VWF_E46-1) and the reverse was located across the junction 
of exon 47-48 (VWFR46/47-2). 
X-chromosome inactivation 
The X-chromosome inactivation profile studies were performed on DNA extracted from 
peripheral blood. The study was done using HpaII digestion. Genomic DNA samples were 
digested with the methylation-sensitive enzyme HpaII (Invitrogen) and subjected to PCR 
amplification of the highly polymorphic CAG repeat sequence in the first exon of the human 
androgen receptor gene (HUMARA), with specific fluorescent primers. The primer sequences 
are shown in Online Supplementary Table S1. The PCR products, both before and after HpaII 
digestion, were electrophoresed on an automated DNA sequencer (ABI 3130XL; Applied 
Biosystems, Warrington, United Kingdom) and analyzed by GeneMapper software (Applied 
Biosystems).2 
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Table S1. Specific primers used for amplification and sequencing by Sanger of VWF RNA. 
 
Forward Primer Location Reverse Primer Location Purpose  Product size 
VWRNA1-1 
CTACATAACAGCAAGACAGTCC 
Exon 1 
VWRNA1-2 
GGTGCTCTTCAGAAGCTGG 
Exon 7 
Full-length VWF 
amplification 
836 bp 
VWRNA2-1 
GCAGCTCATGCAACATCTCC 
Exon 6 
VWRNA2-2 
CCTTGTGAAACTGAAGCATGG 
Exon 12 
Full-length VWF 
amplification 
762 bp 
VWRNA3-1 
CCATTGTCATTGAGACTGTCCAC  
Exon 11 
VWRNA3-2 
CCTGACCTGCCGCTCTCT  
Exon 16 
Full-length VWF 
amplification 
744 bp 
VWRNA4-1    
GCGTGGCGCGAGCCAGG  
Exon 15 
VWRNA4-2 
GTAACCCTGGGACCTTTCG  
Exon 21 
Full-length VWF 
amplification 
796 bp 
VWRNA5-1   
CATGGCCCACTACCTCACC 
Exon 20 
VWRNA5-2 
GGTGGTGACCTGGAGGAC 
Exon 25 
Full-length VWF 
amplification 
752 bp 
VWRNA6-1  
TCCTGTGAGTCCATTGGGG 
Exon 25 
VWRNA6-2 
GGAAGCGACCGTCAGAGC 
Exon 28 
Full-length VWF 
amplification 
750 bp 
VWRNA7-1 
CTTTGTGGTGGACATGATGG 
Exon 28 
VWRNA7-2 
CCTCTCTGACCACAGCTTC 
Exon 28 
Full-length VWF 
amplification 
876 bp 
VWRNA8-1     
CCTGCAGCGGGTGCGAG 
Exon 28 
VWRNA8-2 
CCTGGTCACGGACGTCTC 
Exon 31 
Full-length VWF 
amplification 
728 bp 
VWRNA9-1 
AAATCGGGGATGCCTTGGG 
Exon 30 
VWRNA9-2 
GGAGGTGACGGTGAATGGG 
Exon 35 
Full-length VWF 
amplification 
772 bp 
VWRNA10-1 
GGAGGTGATTCTCCATAATGG 
Exon 35 
VWRNA10-2 
CTGCGTTGTGCAGTTGACC 
Exon 39 
Full-length VWF 
amplification 
930 bp 
VWRNA11-1  
GTGAGCATGGCTGTCCCC 
Exon 38 
VWRNA11-2 
GGATGCCGTGATGGGCCT 
Exon 43 
Full-length VWF 
amplification 
753 bp 
VWRNA12-1 
GTGTGTCCACCGAAGCACC 
Exon 43 
VWRNA12-2 
CCCTTTGATGAACACAAGTGT 
Exon 49 
Full-length VWF 
amplification 
813 bp 
VWRNA13-1 
CGTGATGAGACGCTCCAGG  
 Exon 49 
VWRNA13-2 
CCTCTGCATGTTCTGCTCTT  
Exon 52 
Full-length VWF 
amplification 
546 bp 
VWRNA3-1 
CCATTGTCATTGAGACTGTCCA 
Exon 11 
VWRNA_E15-2  
CGTCGTAGCGGCAGTTCC 
Exon 15 
primers to avoid alternative 
splicing in leukocytes 
564 bp 
VWFR4-1     
GCCTCTCCGTGTATCTTGG 
Exon 4 
VWRNA1-2B 
GGTGCTCTTCAGAAGCTGG 
Exon 7 Exon 5-6 446 bp 
VWF22-1 
GGTCCTGAAGCAGACATACC 
Exon 22 
VWF26-2A  
CTCCCGGAGATTCCTCTCC 
Exon 26 Exon 25 complete 466 bp 
VWFR24/25-1   
GACTGCAACAAGCTGGTGG 
Junction exon 
24-25 
VWF_E25-2  
ATCCAGTCCCTACTAACACT 
Intron 25 Intron 25 retention 301 bp 
VWF_E26-1 
ACATAGCAAGACCCCATCTG 
Intron 25 
VWFR26/27-2 
CATCCAGGATTTTCCCTGG 
Junction exon 
26-27 
Intron 25 retention 401 bp 
VWFR43/44-1  
GGACAGCTGTCGGTCGGG 
Junction exon 
43-44 
VWF_E45-2  
CAGGAGCCAAAAGTGGAAAG 
Intron 45 Intron 45 retention 381 bp 
VWF_E46-1 
CGACCGATACAGGAGGGAG 
Intron 45 
VWF47/48-2  
ATTTTCTTCCTTGTAACCCAGG 
Junction exon 
47-48 
Intron 45 retention 295 bp 
VWFR41/42-1 
 CCCAACTTCACCTGCGCC 
Junction exon 
41-42 
VWFR44/45-2  
TGGGAGCCGACACTCTTCC  
Junction exon 
44-45 
Exon 43 complete 494 bp 
 
At the top of the table, primers previously designed by Corrales et al.1 At the bottom of the table, primers 
newly designed to analyze potential splice site mutations included in this study. 
 
 
  
Table S2. Additional laboratory and clinical data of VWD patients 
 
Patients 
code 
VWD Hospital  Registry code Age Sex ABO Multimeric pattern BS 
Family 
history 
UMP01 3 carrier CHUC P64’s mother 37 F A ND 0 Yes 
UMP02 1H CHUAC C01P034F17 32 M O+ NORMAL 2 Yes 
UMP03 1 CHUAC C01P080 40 M O+ ND 1 NA 
UMP04 1 HUVH - 38 F O+ ND C, D No 
UMP05 1 CHUAC C01P006F03 39 F O+ NORMAL 11 No 
UMP06 2A/2M CHUAC C01P024F12 33 F O SMEAR 10 No 
UMP07 1 HUVH - 47 M O+ ND B Yes 
UMP08 1 HUVH - 42 M O+ ND B Yes 
UMP09 1 HUVH - 20 F ND ND B, C Yes 
UMP10 3 carrier HUVH - 45 F O ND A, C, E Yes 
UMP11 1 CHUAC C01P051F11 36 M O+ NORMAL 7 Yes 
UMP12 3 HUVH C03P021F25 15 M A ND 10 Yes 
UMP13 2A HUVH C03P048F231 15 F O+ ↓HMWM 0 Yes 
UMP14 1 CHUC P12 10 M ND ND 16 Yes 
UMP15 3 HUVH - 25 F O ND B, E Yes 
 
The subtype 1H (historical) refers to patients previously diagnosed as type 1 VWD that, at the time of 
enrollment at the PCM-EVW-ES project, show a slight decrease or even a normal VWF plasma levels. Bleeding 
scores calculated with the International Society on Thrombosis and Haemostasis bleeding assessment tools 
(ISTH-BAT) were used to assess bleeding in patients included in the Spanish (PCM-EVW-ES) and Portuguese 
registries. In the remaining patients, symptoms were assigned letters: A, easy bruising; B, epistaxis; C, 
prolonged bleeding from wounds; D, menorrhagia; and E, postoperative bleeding. BS indicates bleeding score; 
CHUAC, Complexo Hospitalario Universitario A Coruña, Spain; CHUC, Centro Hospitalar e Universitário de 
Coimbra, Portugal; F, female; HUVH, Hospital Universitari Vall d’Hebron, Barcelona, Spain; HMWM, high 
molecular weight multimers; M, male; NA; not available; ND, not determined and; VWD, von Willebrand 
disease. 
 
 
 
 
 
 
 
 
 
  
Table S3. Summary of the in silico analysis of PSSM 
 
The in silico global score is based on the number of in silico algorithms that predicted a splicing effect. In silico analysis of mutations included in the PCM-ES-EVW registry was performed by 
ALAMUT. In silico analysis of the mutations not included in the PCM-EVW-ES registry was performed individually under the established parameters of each algorithm, as well as NetGene2 
(unavailable in ALAMUT). For HSF and MaxEnt, the sequence analyzed is 50 nucleotides in length. For NetGene2 and Neural Network Splice, the sequence analyzed is the exon length plus 100 
intronic nucleotides at the exon ends. In the HSF software, if the WT score is above the threshold (65) and the score variation (between WT and Mutant) is below -10%, the mutation is 
considered to break the splice site. In the other case, if the WT score is below the threshold and the score variation is above +10% the mutation is considered to create a new splice site. In the 
MaxEnt software, if the WT score is above the threshold (3) and the score variation (between WT and Mutant) is below -30% the mutation is considered to break the splice site. In the other 
case, if the WT score is below the threshold and the score variation is above +30% the mutation is considered to create a new splice site. AA indicates amino acid; ASS, acceptor splice site; 
DSS, donor splice site; ESS, exonic splicing silencer; ESE, exonic splicing enhancer; HSF, Human Splicing Finder; MaxEnt, Maximum Entropy; NP not predicted; NT, nucleotide and; PSSM, 
potential splice site mutation. 
 
 
 
Table S4. Analysis of mRNA aberrant transcript expression by next-generation sequencing 
Patient 
code 
Mutation  mRNA probes Leukocytes Platelets 
   % Patient Reads % Control  Reads  % Patient Reads % Control Reads  
UMP01 c.1533+1G>A 
WT 28 % 100 % 100 % 100 % 
Exon 13 skipping (r.1433_1533del) 19 % 0 % 0 % 0 % 
Exon 13+14 skipping (r.1433_1729del) 45 % 0 % 0 % 0 % 
Exon 14 skipping (r.1534_1729del) 8 % 0 % 0 % 0 % 
UMP02 c.3379+1G>A 
WT 56 % 100 % 99 % 100 % 
Exon 25 Skipping (r.3223_3379del) 43 % 0 % 1 % 0 % 
Activation of a cryptic site at +126 nt in exon 25 (r.3349_3379del) ‡ 1.4 % 0 % 0 % 0 % 
UMP03 c.5664+2T>C 
WT 61 % 100 % 97 % 100 % 
Exon 33 skipping (r.5621_5664del) 37 % 0 % 0 % 0 % 
Exon 33+34 skipping (r.5621_5842del) ‡ 2 % 0 % 3 % 0 % 
UMP08 c.546G>A 
WT 98 % 99 % NA - 
Exon 6 skipping (r.533_657del) ‡ 2.3 % 1 % NA - 
UMP10 p.Cys370Tyr 
WT 79 % 100 % 100 % 100 % 
Exon 9 skipping (r.998_1109del) 13 % 0 % 0 % 0 % 
Exon 8+9 skipping (r.875_1109del) 7 % 0 % 0 % 0 % 
UMP11 p.Pro1079_Tyr1080insLeuGlnValAspProGluPro 
WT 86 % 98 % 87 % 100 % 
p.Pro1079_Tyr1080insLeuGlnValAspProGluPro 14 % 2 % 13 % 0 % 
UMP12 c.7082-2A>G 
WT 76 % 100 % 100 % 100 % 
Activation of a cryptic site at +7 nt in exon 42 (r.7082_7088del) 24 % 0 % 0 % 0 % 
UMP14 c.7437G>A 
WT 58 % 99 % NA - 
Exon 43 skipping (r.7288_7437) 12 % 0 % NA - 
Activation of a cryptic splice site at +146 nt  in exon 43 
(r.7434_7437del) 
30 % 1 % NA - 
UMP15 
c.546G>A* Exon 6 skipping (r.533_657del) 3 % 100 % 11 % 100 % 
c.7082-2A>G* Activation of a cryptic site at +7 nt in exon 42 (r.7082_7088del) 6 % 0 % 0 % 0 % 
c.8155+3G>C † Exon 50 skipping (r.8116_8155del) 95 % 0 % 95 % 0 % 
The values correspond to the percentage of the total reads aligned to the aberrant mRNA probes, setting as 100% the sum of reads aligned against the aberrant mRNA 
probes and reads aligned against the wild-type mRNA probes. NA indicates not available; and WT, wild-type. *Mutations in cis. †Mutations in trans. ‡Transcripts with low % 
of reads in leukocytes. 
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Figure S1. Flow chart used to analyze the effect of the mutation on mRNA using next-generation 
sequencing. ROI indicates regions of interest; NGS, next generation sequencing and; SV, 
structural variants.  
  
  
Figure S2. Schematic representation of alignment of NGS reads (from complete amplification of 
VWF mRNA from control platelets and leukocytes) to the VWF mRNA reference sequence. 
Because leukocytes show a predominant alternative splicing resulting in deletion of exon 14 (its 
start is shown with a discontinuous line) and exon 15, no reads were identified and mapped in 
this region. Except for exons 14 and 15 in leukocytes, all regions are presented with a minimum 
coverage of 10X in leukocytes and platelets. 
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 Figure S3. Analysis of the c.1533+1G>A mutation in patient UMP01. A) RT-PCR products 
amplified with primers located in exons 11 and 15 in RNA from leukocytes (L) and platelets (P) 
and separated on 1% agarose gel. Grouping of images from different parts of the same gel.  B) 
Traditional Sanger sequencing of PCR product from patient L (1) showed the WT mRNA 
sequence, L (2) demonstrated exon 13 skipping and L (4) demonstrated exon 13 and 14 skipping. 
The L (3) band could not be purified in the agarose gel due to low concentration, thus it was not 
analyzed by Sanger. Platelets showed the WT mRNA sequence, indicating that the mutated allele 
had been degraded by NMD. C) Schematic representation of the mutation in genomic DNA and 
its effect on the VWF mRNA sequence. M indicates a 100-bp DNA ladder. 
 
  
  
Figure S4. Analysis of the c.3379+1G>A mutation in patient UMP02. A) RT-PCR products 
amplified with primers located in exons 22 and 26 in RNA from leukocytes (L) and platelets (P) 
and separated on 1% agarose gel. Grouping of images from different parts of the same gel.   B) 
Traditional Sanger sequencing of PCR product from patient L (2) showed exon 25 skipping. No 
changes were seen in the mRNA sequence in platelets, indicating that the mutated allele had 
been degraded by NMD. C) NGS of PCR products obtained from patient leukocytes identified 
two splicing variants: exon 25 skipping and activation of a cryptic splice site—DSS 31 nt upstream 
to WT-DSS—in exon 25. This last aberrant transcript was identified in a really low of transcripts. 
D) Schematic representation of the mutation in genomic DNA and its effect on the VWF mRNA 
sequence. M indicates 100-bp DNA ladder and; WO, without. 
  
  
 
Figure S5. A) Pedigree of patient UMP09. The siblings, UMP09 and UMVW0701, showed the 
p.Ala430Gly mutation in the F8 gene in the X chromosome with the 222 peak. The arrow shows 
the index case. B) In patient UMP09, included in this study, her maternally-derived (UMVW0803) 
allele (222) was completely digested by the methylation-sensitive restriction enzyme Hpa II and, 
therefore, was not amplified by PCR. The remaining peak (234) is the paternally-derived allele 
representing the inactive, methylated X chromosome that resisted cleavage by Hpa II and was 
successfully amplified. Thus, this female patient shows complete skewing of X inactivation 
corresponding to the WT F8 gene. The UMHA1591 sample is a positive control for skewing of X 
inactivation. 
 
  
  
Figure S6. Analysis of the c.3223-7_3236dup mutation in patient UMP11. A) RT-PCR products 
amplified with primers located in exons 22 and 26 in RNA from leukocytes (L) and platelets (P) 
and separated on 1% agarose gel. B) Traditional Sanger sequencing of PCR product from patient 
L and P showed insertion of 21 nucleotides. Same results were observed by NGS (data not 
shown). C) Schematic representation of the mutation in genomic DNA and its effect on the VWF 
mRNA sequence. M, 100-bp DNA ladder. 
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